NCT04608487View on ClinicalTrials.gov

Axi-cel in CNS Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

June 14, 2025

Study Completion Date

June 14, 2038

Conditions

LymphomaLymphoma Cns

Interventions

DRUG

Fludarabine

Intravenous infusion

DRUG

Cyclophosphamide

Intravenous infusion

BIOLOGICAL

Axicabtagene Ciloleucel

Intravenous infusion

Trial Locations (2)

02115

Dana Farber Cancer Institute, Boston

02215

Brigham and Women's Hospital, Boston

All Listed Sponsors

collaborator

Kite, A Gilead Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER